Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 14, 2014

View Archived Issues

MiniVax and University of Rochester enter into option agreement for antibody against pneumonia

Daiichi Sankyo aims to expand pipeline through collaboration with Virtici and Celdara Medical

Zymeworks and ImClone Systems to develop bispecific antibodies

FORMA Therapeutics advances cancer collaboration with Boehringer Ingelheim

Discovery of a novel compounds for the treatment of multidrug-resistant tuberculosis

Acetylon presents results from early clinical trials of ACY-1215 in multiple myeloma

Researchers present results and collaboration agreement on Bordetella pertussis vaccine technology

Development of a water-tight light-activated surgical adhesive for minimally invasive tissue repair

Alnylam acquires Sirna Therapeutics

AnaptysBio developing first-in-class anti-IL-33 therapeutic antibody

FDA accepts idelalisib NDA for refractory indolent NHL

Phase II study of CRLX-101 in ovarian cancer meets primary endpoint

EMA accepts Biovest's MAA for BiovaxID

Enanta Pharmaceuticals begins phase I study of EDP-788

Fibrocell Science and Intrexon expand collaboration

AstraZeneca patents detail novel BACE1 inhibitors

Actelion Pharmaceuticals divulges chemokine CXCR7 receptor agonists

Roche reports development of LPA1 receptor antagonists

Monoclonal antibody Hu3F8 receives FDA orphan drug status for osteosarcoma

Jazz Pharmaceuticals acquires rights to ADX-N05 from Aerial BioPharma

Alexion and Moderna enter agreement to develop mRNA Therapeutics for rare diseases

Lilly acquires a CGRP antibody for migraine prevention from Arteaus Therapeutics

Merck & Co. begins rolling submission of BLA for MK-3475

Phase II trial shows APG-101 prolongs overall survival in glioblastoma patients

Cubist files application to conduct first-in-human study of CB-618 in the Netherlands

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...